Last $184.16 USD
Change Today +5.01 / 2.79%
Volume 2.9M
SHPG On Other Exchanges
Symbol
Exchange
SHPG is not on other exchanges.
As of 2:57 PM 10/20/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

5 Riverwalk

Citywest Business Campus

Dublin, 24

Ireland

Phone: 353 1 429 7700

Fax:

as a once-daily monotherapy treatment of ADHD in children and adolescents aged 6 to 17 and as adjunctive therapy to stimulants in 2011. It is available in 1mg, 2mg, 3mg and 4mg tablets. INTUNIV XR was approved by Health Canada as monotherapy for the treatment of ADHD in children aged 6 to 12 years and as adjunctive therapy to psychostimulants for the treatment of ADHD in children, aged 6 to 12 years, with a sub-optimal response to psychostimulants in 2013 and was launched in Canada in 2013. EQUASYM The company owns the worldwide rights (excluding the United States, Canada and Barbados) to EQUASYM immediate release and modified release (XL) preparations for the treatment of ADHD in children and adolescents aged 6 to 17. The company is focusing exclusively on the XL form. As of December 31, 2013, EQUASYM XL was commercially available in 10 countries in 10mg, 20mg and 30mg strengths. EQUASYM XL is marketed in Mexico and South Korea under the trade name METADATE CD. Treatments for Ulcerative Colitis (UC) UC is a serious chronic inflammatory disease of the colon in which part or all of the large intestine becomes inflamed and often ulcerated. LIALDA/MEZAVANT LIALDA is indicated in the United States and Canada for the induction of remission in patients with mild to moderately active UC and for the maintenance of remission of UC. The addition of the indication for maintenance of remission of UC was approved by Health Canada and by the FDA. LIALDA is the FDA-approved once-daily oral formulation of mesalamine indicated for the induction and maintenance of remission. LIALDA contains the commercially available mesalamine dose per tablet (1.2g), so patients can take as few as two tablets once daily. In 2012, the FDA issued draft bioequivalence guidelines for orally-delivered delayed or extended-release mesalamine-based drugs. LIALDA was approved by the FDA and was launched in the United States. PENTASA PENTASA controlled release capsules are marketed by Shire in the United States and are indicated for the induction of remission and for the treatment of patients with mild to moderately active UC. PENTASA is an ethylcellulose-coated, controlled release capsule formulation designed to release therapeutic quantities of mesalamine throughout the gastrointestinal tract. PENTASA is available in the United States in 250mg and 500mg capsules. In 2012, the FDA issued draft bioequivalence guidelines for generic approvals of orally-delivered delayed or extended-release mesalamine-based drugs (including LIALDA and PENTASA). RESOLOR RESOLOR is the first of a new generation of selective, high-affinity 5-HT4 receptor agonists that stimulates gastrointestinal motility and acts primarily on different parts of the lower gastrointestinal tract (prokinetic). In 2009, RESOLOR was approved by the European Medicines Agency (EMA) throughout the EU as a once daily oral treatment for symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief. RESOLOR is available in 1mg and 2mg dose strengths, both for once-daily dosing. As of December 31, 2013, RESOLOR was available in 18 EU countries. In 2012, the company announced that it had acquired the rights to develop and market prucalopride in the United States pursuant to an agreement with Janssen Pharmaceutica N.V., part of the J&J Group. Treatments for Rare Diseases REPLAGAL REPLAGAL is marketed for the treatment of Fabry disease outside of the United States Fabry disease is a rare, inherited genetic disorder resulting from a deficiency in the activity of the lysosomal enzyme alpha-galactosidase A, which is involved in the breakdown of fats. Although the signs and symptoms of Fabry disease vary widely from patient to patient, the most common include severe pain of the extremities, impaired kidney function, which often progresses to kidney failure, early heart disease, stroke and disabling gastrointestinal symptoms. The disease is estimated to affect 1 in 27,000 people (Spada et al, 2006). REPLAGAL is a fully human alpha-galactosidase A protein made in human cells that replaces the deficient alpha-galactosidase A with

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SHPG:US $184.16 USD +5.01

SHPG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Allergan Inc/United States $181.00 USD +3.51
CSL Ltd A$74.48 AUD -0.17
Mylan Inc/PA $50.10 USD +0.64
UCB SA €62.60 EUR -1.49
Valeant Pharmaceuticals International Inc C$139.13 CAD +3.69
View Industry Companies
 

Industry Analysis

SHPG

Industry Average

Valuation SHPG Industry Range
Price/Earnings 21.7x
Price/Sales 6.5x
Price/Book 5.7x
Price/Cash Flow 32.2x
TEV/Sales 6.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SHIRE PLC-ADR, please visit www.shire.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.